Search Results

Chronic Myeloid Leukemia (CML)

Chronic Lymphocytic Leukemia (CLL)

Leukemia Research Funded by LLS

Working for The Leukemia & Lymphoma Society

Update on Acute Lymphoblastic Leukemia

A Brave Kid’s Guide to Leukemia

A Brave Kid’s Guide to Leukemia by Nina Gonzalez, MD
Hello Brave Co, 2024, 49 Pages, Paperback
ISBN: 979-8990710511

Charlie is a curious kid facing a big challenge: leukemia. With so many questions swirling in his mind, Charlie finds a friend in Cobi, the super smart Brave Buddy who helps kids understand their medical diagnoses. Together, they set off on a journey of understanding, and Charlie realizes just how Brave he is.

A Brave Kid's Guide to Leukemia is designed to help children understand their leukemia diagnosis. Created by Dr. Nina Gonzalez and the Hello Brave team, this book breaks down complex medical information into simple, clear language and illustrations. Through an engaging conversation between Cobi and Charlie, this book helps to dispel common misconceptions and provides comfort through a shared understanding of this challenging diagnosis. At the end of the book, you'll find a glossary of easy-to-understand terms, guides for adults on how to talk about tough diagnoses like leukemia with kids, questions to ask your care team, and a Brave Kid Certificate to honor your child's bravery and strength. This book is a supportive tool for both patients and families dealing with leukemia.


For more information click here
 

Suggested Reading A Brave Kid’s Guide to Leukemia
Audience
Teens & Children

Curing AML in Elderly Patients

Robert Hromas, M.D., a blood cancer expert at the University of Florida's College of Medicine, is looking to discover new drugs that will improve the response of elderly AML patients to chemotherapy. His latest research, funded through a Translational Research Program grant from The Leukemia & Lymphoma Society, focuses on inhibiting the DNA repair response.

Overcoming RAS-driven Mechanisms of Resistance in Leukemia

The mitogen-activated protein kinase (MAPK) pathway is activated in high-risk leukemia and is a hallmark of resistance to therapies. This project uses patient-derived xenograft models of relapsed pediatric ALL and AML with activated RAS/MAPK to test whether clinically relevant MAPK mutations activate the VAV3/RAC pathway and if pharmacological inhibition of that pathway by a small molecule we developed synergizes with a MAPK-inhibitor to provide a new treatment strategy for RAS-driven leukemia.

A Day in LLS History

On October 20, 1944, Robert “Robbie” Roesler de Villiers was only 16 years old when he died from leukemia. Robbie’s parents, Rudolph and Antoinette, were stricken with grief and frustrated by the lack of effective treatments for what was then considered a hopeless disease.

After five years of mourning their son, they started a fundraising and education organization in his name. The Robert Roesler de Villiers Foundation had only a few volunteers and a tiny budget.

Doctor in white lab coat looking at tablet with patient

What Is Blood Cancer?

Reviewed by Gwen Nichols, MD, EVP and Chief Medical Officer at The Leukemia & Lymphoma Society

Genomics of childhood leukemia: Analysis of diverse, worldwide populations

Common genetic variation explains a large share of childhood leukemia in children of European ancestry and may explain the differing incidence in children of other ancestries. The Childhood Cancer and Leukemia International Consortium seeks to better understand the genomic architecture of childhood leukemia risk using its collective genomic datasets comprising >20,000 diverse children with leukemia. The results will inform risk prediction for and possibly prevention of childhood leukemia.

Combination Targeted Therapy in Chronic Lymphocytic Leukemia

Targeted therapies have replaced chemoimmunotherapy in chronic lymphocytic leukemia (CLL). We previously reported that combined BTK inhibitor (ibrutinib) and BCL2 antagonist (venetoclax) is highly synergistic. In this proposal, we will conduct a phase II trial of combined non-covalent BTK inhibitor (pirtobrutinib) with venetoclax and obinutuzumab in patients with untreated CLL with primary endpoint of marrow MRD. We will perform BH3 profiling and scRNAseq and correlate with clinical outcomes.

Targeted combination therapies for leukemia with NUP98 translocations

Leukemia patients with chromosomal translocations of the Nucleoporin (NUP98) gene suffer from very poor prognosis. In this project we will identify new treatment for these patients by combining menin inhibitor with FDA approved drugs. We will evaluate effectiveness, mechanism of action and biomarkers of treatment response to these combinations in advanced pre-clinical models of NUP98 leukemia. We expect these studies will lead to future clinical trials in AML patients with NUP98 translocations.

Surviving AML: The Long Road Back

“Hola,” I said playfully, as I answered my cell phone on a beautiful Saturday -- April 21, 2012. “This is Dr. so and so. I’m calling because your blood work from yesterday is all out of whack.” “What do you mean, ‘Out of whack?’” “Your white blood cell count is high,” he said. “What’s high? “It's at 63,000.” “And what's it supposed to be?” “10,000.”

Abrale (Brazilian Lymphoma and Leukemia Society)

To support cures and improve the quality of life for people living with blood cancer in Brazil.

  • Serves Brazil and Latin America
  • Provides disease, treatment and clinical trial information as well as materials about blood cancers
  • Offers psychological, legal, nutritional support and more
  • Advocates for patient access to treatment

Patients, caregivers, health professionals

Website or +55 11 3149-5190 http://www.abrale.org.br/
International Resources
International Resources

Shared Decision Making in Chronic Leukemias

Advances in Acute Myeloid Leukemia (AML)

Spotlight On Chronic Myeloid Leukemia (CML)

Spotlight On Acute Myeloid Leukemia (AML)

Children’s Leukemia Research Association (CLRA)

To support research efforts towards finding the causes and cure for leukemia.

  • Patient Aid Program offers limited funds (up to $3,000 per year) to assist with certain treatments, services and prescriptions; funds are available on a first-come, first-serve basis
  • CLRA funds grants to doctors conducting promising research about leukemia.

Children and adults with blood cancer in the U.S., healthcare professionals and researchers

516-222-1944 http://www.childrensleukemia.org/
International Resources
Canadian Resources U.S. Resources

Spotlight on Chronic Lymphocytic Leukemia (CLL)

Update On Chronic Lymphocytic Leukemia (CLL)

Insight into Chronic Myeloid Leukemia (CML)

Acute Leukemia Advocates Network (ALAN)

To change the outcomes of acute leukemia patients by strengthening patient advocacy.

  • ALAN is an independent global network of patient organizations which aims to increase awareness about the acute leukemias, share best practices, advocate for better access and treatment, and improve education for healthcare professionals.

Healthcare professionals, patient advocates

Website http://acuteleuk.org/
International Resources
Canadian Resources International Resources U.S. Resources

What’s on the Horizon for Chronic Lymphocytic Leukemia?